Non-alcoholic fatty liver disease

46,187views

Non-alcoholic fatty liver disease

GI

GI

Viral hepatitis
Viral hepatitis: Clinical
Hepatitis A and Hepatitis E virus
Neonatal hepatitis
Hepatitis B and Hepatitis D virus
Hepatitis C virus
Autoimmune hepatitis
Viral hepatitis: Pathology review
Jaundice: Clinical
Cirrhosis: Clinical
Cirrhosis: Pathology review
Liver anatomy and physiology
Cirrhosis
Primary biliary cholangitis
Portal hypertension
Non-alcoholic fatty liver disease
Alcohol-associated liver disease
Cholestatic liver disease
Jaundice: Pathology review
Bile secretion and enterohepatic circulation
Hepatitis medications
Waterhouse-Friderichsen syndrome
Acute pancreatitis
Pancreatitis: Clinical
Pancreatitis: Pathology review
Chronic pancreatitis
Peptic ulcer
GERD, peptic ulcers, gastritis, and stomach cancer: Pathology review
Peptic ulcers and stomach cancer: Clinical
Gastrointestinal bleeding: Clinical
Achalasia
Esophageal cancer
Diffuse esophageal spasm
Barrett esophagus
Gastroesophageal reflux disease (GERD)
Gastric cancer
Gastritis
GERD, peptic ulcers, gastritis, and stomach cancer: Pathology review
Esophageal disorders: Pathology review
Gastrointestinal bleeding: Pathology review
Acid reducing medications
Jaundice: Pathology review
Cirrhosis: Pathology review
Gastroesophageal reflux disease (GERD): Clinical
Esophageal surgical conditions: Clinical
BRUE, ALTE, and SIDS: Clinical
Esophagitis: Clinical
Esophageal disorders: Clinical
Inflammatory bowel disease: Pathology review
Inflammatory bowel disease: Clinical
Bowel obstruction: Clinical
Irritable bowel syndrome
Bowel obstruction
Ulcerative colitis
Diverticulosis and diverticulitis
Diverticular disease: Pathology review
Diverticular disease: Clinical
Abdominal pain: Clinical
Microscopic colitis
Ischemic colitis
Clostridium difficile (Pseudomembranous colitis)
Peritonitis
Abdominal trauma: Clinical
Small bowel ischemia and infarction
Malabsorption syndromes: Pathology review
Meckel diverticulum
Zenker diverticulum
Celiac disease
Celiac disease: Nursing process (ADPIE)
Malabsorption: Clinical
Diarrhea: Clinical
Acute cholecystitis
Chronic cholecystitis
Gallbladder disorders: Clinical
Biliary colic
Gallstones
Gallstone ileus
Ascending cholangitis
Gallbladder carcinoma
Primary sclerosing cholangitis
Jaundice: Clinical
Cirrhosis: Clinical
Pediatric gastrointestinal bleeding: Clinical
Wernicke-Korsakoff syndrome
Hepatic encephalopathy
Dementia and delirium: Clinical
Alpha 1-antitrypsin deficiency
Dementia: Pathology review
Laxatives and cathartics
Seizures: Clinical
Disorders of consciousness: Clinical
Alcohol use disorder
Alcohol-associated liver disease
Fetal alcohol syndrome
Substance misuse and addiction: Clinical
Anticonvulsants and anxiolytics: Barbiturates
Psychiatric emergencies: Pathology review
Hypomagnesemia
Sideroblastic anemia
Gluconeogenesis

Transcript

Watch video only

Nonalcoholic fatty liver disease is actually a spectrum of disease, going from least to most severe—steatosis, steatohepatitis, fibrosis, and finally cirrhosis.

Nonalcoholic fatty liver disease results from fat deposition in the liver, which is unrelated to alcohol or viral causes.

Typically, it affects individuals with metabolic syndrome, which includes a combination of three of the following five diagnoses: obesity, hypertension, diabetes, hypertriglyceridemia, and hyperlipidemia.

Given how common metabolic syndrome has become, it’s not surprising that the rate of nonalcoholic fatty liver disease has also increased dramatically.

It’s a massive problem growing in lock-step with expanding waistlines, affecting about three quarters of all obese individuals, including many children.

Although the exact mechanism of nonalcoholic fatty liver disease isn’t clear, insulin resistance seems to play an important role.

Over time, insulin receptors on various tissues including the liver become less responsive to insulin, and as a result the liver goes into a mode where it increases fat storage and decreases fatty acid oxidation.

That means decreased secretion of lipids into the bloodstream, in the form of lipoproteins, and increased synthesis and uptake of free fatty acids from the blood, a process called steatosis.

Steatosis causes fat droplets to form within hepatocytes, some of which become large enough to cause the hepatocytes to swell up with fat and push the nuclei to the edge of the cell.

You can see this on a histopathology slide of the liver.

All of these white circles are large deposits of fat.

Zooming out and looking at the liver, you see widespread steatosis which makes the liver appear large, soft, yellow, and greasy.

Over time, that fat in the hepatocytes is vulnerable to degradation.

Unsaturated fatty acids, or fatty acids that have at least one double bond in their carbon chain, have hydrogen atoms that are especially vulnerable to initiators such as the reactive oxygen species like the hydroxyl radical that have an unpaired electron.

In this example the hydroxyl radical pairs with the vulnerable lipid hydrogen to make water and a fatty acid radical.

The fatty acid radical is unstable and reacts with non-radicals, including molecular oxygen and undamaged fatty acids.

This goes on until one radical species reacts with another radical species, which terminates the reaction.

This process damages lipid membranes leading to things like mitochondrial dysfunction and eventually cell death.

Cell death generates inflammation, and together the process of steatosis and inflammation is referred to as steatohepatitis.

In the absence of alcohol this is called nonalcoholic steatohepatitis or NASH.

Key Takeaways

Non-alcoholic fatty liver disease (NAFLD) is a condition in which excess fat is deposited in the liver, leading to inflammation and scarring. NAFLD is a common liver disorder that affects people who do not drink alcohol excessively. NAFLD commonly affects people with metabolic syndrome, which includes a combination of three of the following five diagnoses: obesity, hypertension, diabetes, hypertriglyceridemia, and hyperlipidemia.

Symptoms of NAFLD may be subtle or absent in the early stages of the disease. In advanced stages, symptoms may include fatigue, abdominal pain, and jaundice. NAFLD can progress to a more serious condition called non-alcoholic steatohepatitis (NASH), which can lead to liver scarring and cirrhosis. Treatment for NAFLD may involve lifestyle changes such as weight loss, regular exercise, and a healthy diet to help reduce fat in the liver and improve insulin resistance.

Sources

  1. "Robbins Basic Pathology" Elsevier (2017)
  2. "Harrison's Principles of Internal Medicine, Twentieth Edition (Vol.1 & Vol.2)" McGraw-Hill Education / Medical (2018)
  3. "Pathophysiology of Disease: An Introduction to Clinical Medicine 8E" McGraw-Hill Education / Medical (2018)
  4. "CURRENT Medical Diagnosis and Treatment 2020" McGraw Hill Professional (2019)
  5. "The Role of Intestinal Bacteria Overgrowth in Obesity-Related Nonalcoholic Fatty Liver Disease" Nutrients (2014)
  6. "Non-alcoholic fatty liver disease" BMJ (2014)